DCM
JNCE

Delpha Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Delpha Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-824
Closed -$11K – 1367
2017
Q4 		$11K Buy
+824
New +$12.1K 0.01% 1044

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Delpha Capital Management's JNCE Position: Q1 2018 in Review

Delpha Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2018, closing a stake of 824 shares — an estimated $11K sold.

Delpha Capital Management first reported a position in JNCE in Q4 2017 and held it in 1 quarter. The position peaked at $11K in Q4 2017. 94 funds tracked by Wall St. Rank hold JNCE as of Q1 2018.

  • Delpha Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 824 Jounce Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $11K.
  • Delpha Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $11K in Q4 2017.
  • 94 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.